Daiwa Securities Group
WST icon

Daiwa Securities Group’s West Pharmaceutical WST Stock Holding History

Daiwa Securities Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.42M Buy
17,876
+53
+0.3% +$16.2K 0.01% 465
2026
Q1 		$4.47M Buy
17,823
+1,295
+8% +$322K 0.01% 485
2025
Q4 		$4.55M Buy
16,528
+2,903
+21% +$794K 0.01% 484
2025
Q3 		$3.57M Sell
13,625
-420
-3% -$102K 0.01% 519
2025
Q2 		$3.07M Buy
14,045
+1,369
+11% +$293K 0.01% 533
2025
Q1 		$2.84M Buy
12,676
+1,163
+10% +$321K 0.01% 511
2024
Q4 		$3.77M Buy
11,513
+643
+6% +$202K 0.02% 442
2024
Q3 		$3.26M Buy
10,870
+857
+9% +$262K 0.02% 465
2024
Q2 		$3.3M Buy
10,013
+1,273
+15% +$450K 0.02% 431
2024
Q1 		$3.46M Buy
8,740
+753
+9% +$279K 0.02% 410
2023
Q4 		$2.81M Buy
7,987
+739
+10% +$262K 0.02% 433
2023
Q3 		$2.72M Buy
7,248
+568
+9% +$220K 0.02% 419
2023
Q2 		$2.56M Buy
6,680
+268
+4% +$95.7K 0.02% 431
2023
Q1 		$2.22M Buy
6,412
+602
+10% +$176K 0.02% 466
2022
Q4 		$1.37M Buy
5,810
+846
+17% +$200K 0.01% 560
2022
Q3 		$1.22M Buy
4,964
+212
+4% +$64.6K 0.01% 581
2022
Q2 		$1.44M Buy
4,752
+176
+4% +$57.3K 0.01% 543
2022
Q1 		$1.88M Buy
4,576
+236
+5% +$92.4K 0.01% 518
2021
Q4 		$2.04M Buy
4,340
+199
+5% +$85.7K 0.01% 506
2021
Q3 		$1.76M Buy
4,141
+171
+4% +$72.1K 0.01% 525
2021
Q2 		$1.43M Buy
3,970
+194
+5% +$64.1K 0.01% 551
2021
Q1 		$1.06M Buy
3,776
+165
+5% +$47.2K 0.01% 589
2020
Q4 		$1.02M Buy
3,611
+67
+2% +$18.8K 0.01% 566
2020
Q3 		$974K Buy
3,544
+492
+16% +$130K 0.01% 512
2020
Q2 		$465K Hold
3,052
– – 0.01% 554
2020
Q1 		$465K Hold
3,052
– – ﹤0.01% 663
2019
Q4 		$459K Buy
+3,052
New +$444K ﹤0.01% 731

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Daiwa Securities Group's WST Position: Q2 2026 in Review

Daiwa Securities Group increased its West Pharmaceutical (WST) stake by 0.3% in Q2 2026, buying an estimated $16.2K and bringing the position to 17,876 shares worth $6.42M. The position accounts for 0.01% of the portfolio, ranked #465.

Daiwa Securities Group first reported a position in WST in Q4 2019 and has held it in 27 quarters since. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Daiwa Securities Group held 17,876 shares of West Pharmaceutical worth $6.42M as of Q2 2026.
  • Daiwa Securities Group bought 53 West Pharmaceutical shares in Q2 2026, an estimated $16.2K.
  • West Pharmaceutical made up 0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #465 holding.
  • Daiwa Securities Group first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.